Organization | National Center for HIV/AIDS, Dermatology, and STDs, Phnom Penh, Cambodia

National Center for HIV/AIDS, Dermatology, and STDs, Phnom Penh, Cambodia Report issue

Government Phase 3

Organization Overview

First Clinical Trial

2006

NCT00234091

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

National Center for HIV, Dermatology and STD

Active Ingredients

Drugs in Phase 3 Trials (8)

abacavir (ziagen) (1 trial)

efavirenz (sustiva) (1 trial)

lamivudine (epivir) (1 trial)

lopinavir (Kaletra) (1 trial)

nelfinavir (viracept) (1 trial)

nevirapine (viramune) (1 trial)

ritonavir (Norvir) (1 trial)

zidovudine (retrovir) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 3)

HIV Infections (Phase 3)

Infections (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 1
# of Trial APIs: 8